ClinicalTrials.gg
RecruitingNCT01789229Updated Mar 23, 2023

Establishment of a Tumor Bank for Tissue Samples

An observational study in Ovarian Neoplasms, Breast Neoplasms and Colorectal Neoplasms, sponsored by Medical University of Vienna. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Medical University of Vienna · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 65 studies in Ovarian Neoplasms with a site in Austria — 12 open to participants now, 15 under way, 7 of them phase 3. Ovarian Neoplasms · Austria.

Planned enrollment
Largest of 13
10,000 · median 500
Started
2003
with 1 other
Observational
13 of 65
4 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
28th of 65
by date
Lead sponsor
6 of 65
Medical University of Vienna

Among the 65 studies in Ovarian Neoplasms with a site in Austria, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2003, is one of 13 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 28th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

12 of the 65 studies in Ovarian Neoplasms with a site in Austria are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Ovarian Neoplasms with a site in Austria, or all of them as a file.
02

Study summary

Establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and malign tumors) and healthy people as controls. The tissue samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tissue tumor bank.

This tumor bank for tissue samples, together with our tumorbank for blood samples (NCT01763125) combined constitute the entity "Tumorbank".

Read the detailed description

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.

Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.

The aim of this tumor bank is to consist of biological samples (together with a blood bank - see NCT01763125) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

03

Conditions studied

  • Ovarian Neoplasms
  • Breast Neoplasms
  • Colorectal Neoplasms
  • Neoplasms of the Female Genitalia
  • Lung Neoplasms
  • Endocrine Gland Neoplasms

Keywords

  • biobank
  • fresh-frozen tissue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Male and female patients/people. Minimum age 18 years Characteristics: Recruited at the Medical University Vienna or at one of the facilities cooperating with the Vienna Med. University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/Female
  • Age 18 to 90 years max.
  • Just one current known malignant disease or just one current inflammatory disease

Exclusion criteria

Exclusion Criteria:

  • Inflammatory disease and malignant disease
  • multiple
  • multiple diseases
  • underage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Malignant tumors

    Patients who have one of the Neoplasms stated above under "conditions".

    Other: Tumor tissue collection · Other: Sampling of ascites and pleural effusion · Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation

  • Benign controls

    Patients with a benign tumor or an inflammatory disease - to be matched by age.

    Other: Tumor tissue collection · Other: Sampling of ascites and pleural effusion · Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation

  • Healthy controls

    People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.

    Other: Collecting urine samples · Other: Collecting saliva sample · Other: Collecting sputum · Other: Collecting stool samples · Other: Lavage/Irrigation

Interventions

  • OtherTumor tissue collection

    Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon. Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis. Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger.

  • OtherSampling of ascites and pleural effusion

    Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.

  • OtherCollecting urine samples

    Patient is asked to give a urine sample. Urine is collected in urine beaker.

  • OtherCollecting saliva sample

    Saliva sample is collected by spatula from the mouth cavity of the patient.

  • OtherCollecting sputum

    Patient is asked to produce sputum into a 50ml lab tube.

  • OtherCollecting stool samples

    Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.

  • OtherLavage/Irrigation

    Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.

06

What researchers measure

Primary outcomes

  1. Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.

    Time frame: 14 years

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010 Apr 1;29(13):1997-2004. doi: 10.1038/onc.2009.482. Epub 2010 Jan 18. PubMed 20101229 ↗
  • Tong D, Heinze G, Pils D, Wolf A, Singer CF, Concin N, Hofstetter G, Schiebel I, Rudas M, Zeillinger R. Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. BMC Cancer. 2010 Dec 15;10:682. doi: 10.1186/1471-2407-10-682. PubMed 21159173 ↗
  • Grimm C, Watrowski R, Baumuhlner K, Natter C, Tong D, Wolf A, Zeillinger R, Leodolter S, Reinthaller A, Hefler L. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol. 2011 Jun 1;121(3):537-41. doi: 10.1016/j.ygyno.2011.02.019. Epub 2011 Mar 3. PubMed 21376376 ↗
  • Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N. Delta133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18. PubMed 22009029 ↗
  • Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M. Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer. 2013 Mar 1;119(5):946-54. doi: 10.1002/cncr.27850. Epub 2012 Oct 23. PubMed 23096450 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2013
First posted
Feb 12, 2013
Start
Sep 2003
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01789229
Responsible party
Robert Zeillinger, Dr.phil. (Univ.Prof. Dr., Medical University of Vienna) — Principal investigator
First posted
Feb 12, 2013
Start date
Sep 2003
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 23, 2023

Study contacts

Robert Zeillinger, Prof.Dr.
Contact
robert.zeillinger@meduniwien.ac.at
+43140400 ext. 78310
Eva Obermayr, PhD
Contact
eva.obermayr@muv.ac.at
+4340400 ext. 78270
Robert Zeillinger, Prof.Dr.
principal investigator · Medical University of Vienna, Dptm. of Obstetrics & Gynaecology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion